secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0001493152-22-005894
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech appoints Robert Dickey IV as CFO; Lintal transitions to consultant
--------------------------------------------------------------------------------

- Robert Dickey IV becomes CFO effective April 4, 2022, replacing Ellen Lintal who moves to consultant role.
- Dickey compensated $375/hour under a one-year consulting agreement with his firm Foresite Advisors.
- Dickey brings 25+ years of life science CFO and investment banking experience, including 18 years at Lehman Brothers.
- He previously served as senior vice president of AIM from 2008 to 2013.
- Press release issued March 3, 2022; contract terminable on 60-day notice (non-cause) or 30-day (cause).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315222005894/0001493152-22-005894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315222005894/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-005894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer